Navigation Links
Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:2/8/2011

CAMBRIDGE, Mass., Feb. 8, 2011 /PRNewswire/ -- Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

Vascugel, a novel endothelial cell-based therapy and Pervasis' lead development program, aims to regulate the body's healing response following surgical interventions to create vascular access points which are necessary for ESRD patients undergoing hemodialysis, reducing the need for repeat surgical interventions and improving overall patient outcomes.

FDA established Fast Track to facilitate the development and accelerate the pre-market review of treatments for serious and life-threatening conditions, so that these products can reach approval more rapidly. To receive Fast Track designation, a product must address a serious unmet medical condition, and be supported by strong results from pre-clinical or clinical testing demonstrating the product potential.

Vascugel has demonstrated clinical proof of concept in two Phase 2 clinical trials involving patients with ESRD who require a permanent arteriovenous (AV) access for hemodialysis. In these trials, Vascugel exhibited an excellent safety profile and encouraging efficacy trends were observed, including improved duration of patency (or unimpeded blood flow) and a delay in time to first intervention as compared to placebo.

"The fact that these very sick patients must endure serious complications and repeat surgical procedures so that they can continue undergoing hemodialysis represents a significant unmet medical need—one that Vascugel is uniquely able to address," stated Frederic Chereau, president and CEO of Pervasis. "Fast Track designation from the FDA further validates Vascugel's potential as a safe and effective therapy for patients with end stage renal disease, and will help accelerate the
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
2. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
3. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
4. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
5. Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
6. China Medicine Corporation Receives Manufacturing License for rADTZ
7. Johnson & Johnson Receives Approval from European Commission
8. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
9. Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
10. China Sky One Medical Receives Medical Industry Awards
11. Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... YORK and RALEIGH, N.C., Oct. 20, 2014 ... Hereditary Neuropathy Foundation (HNF), both philanthropies, announced today ... drug candidates for the treatment of the rare ... BioPontis Alliance announced its alliance model earlier ... a first demonstration of a collaborative model where ...
(Date:10/19/2014)... 20, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its third quarter 2014 financial results on Wednesday, October ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Wednesday, October ...
(Date:10/19/2014)... FRANKFURT , Deutschland, October 19, 2014 /PRNewswire/ ... echten CRT-Fallstudien gefragt. Das Problem dabei ... ihre Informationen mit der Kompetenz zu teilen. ... zusammenzustellen, und deshalb freuen wir uns umso mehr, ... Pharmafirmen gebeten, ihre Gepflogenheiten bei Kühlketten aufzuschreiben - ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2
(Date:10/20/2014)... It’s hard to imagine what it’s like ... children around the world, it’s a reality. And while new ... are forced to walk barefoot on rocky terrain or sewage-lined ... with their friends. , Buckner International's Shoes for ... in October to encourage support for Air1 and while ...
(Date:10/20/2014)... October 20, 2014 Do you ever ... Here comes a wonderful app Metassessor for teachers, specialists ... company helped its client “Intervention Development LLC” to ... app is designed for iOS 4.3 or later and ... app is optimized for iPhone 5. It is now ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, BambooIndustry.com, ... has unveiled its new range of bamboo deckings ... for these natural items; they are now available at ... most people, it is hard to overstate the significance ... of attention to online services. The company’s workers are ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
(Date:10/19/2014)... October 20, 2014 SweetDressy.com, a professional ... announced its promotion for long evening dresses . ... the special offer; the current discount is up to ... the industry pioneers in the fashion field. Its dress ... ladies dwelling in various parts of the world. All ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... Senegal, March 25 The U.S. Agency for ... Assistance (OFDA) is providing more than $3.7 million ... increase food security of families in Senegal.Of this ... improve community-based nutrition efforts and agriculture production in ...
... 25 Globus Medical, Inc., the largest privately ... announced the launch of MicroFuse(TM) ST Granules, a ... both strength and porosity. MicroFuse(TM) technology utilizes proprietary ... polymers manufactured with a patented microsphere process to ...
... Several cases of inappropriate shocks from appliances have ... -- A literally shocking tale of the potential ... implanted defibrillators comes from cardiologists in Denmark. , ... receiving an implantable cardioverter defibrillator, was readmitted shortly ...
... NATICK, Mass., March 25 Boston Scientific Corporation (NYSE: ... Poor,s Ratings Services has raised the Company,s rating outlook ... credit rating at BB+.The Standard and Poor,s upgrade follows ... the Company,s outlook to stable from negative.Standard and Poor,s ...
... Neonatologists begin new era of treatment to save tiniest babiesCLEVELAND, March 25 ... NICU provides individual rooms with sleep accommodations so parents can stay ... Innovative care design that creates a healing environment with ... Green building materials incorporated throughout NICU. , ...
... One of the Highest Civilian Honors Given to ... March 25 The Congressional Medal of Honor ... Above & Beyond Citizen Honors recipients for ... process, three Americans have been selected for their ...
Cached Medicine News:Health News:Globus Medical's MicroFuse(TM) Technology Engineered for Optimal Strength and Porosity 2Health News:Faulty Household Wiring Can Trigger a Heart Defibrillator 2Health News:Standard and Poor's Raises Boston Scientific's Rating Outlook to Positive 2Health News:Standard and Poor's Raises Boston Scientific's Rating Outlook to Positive 3Health News:Rainbow Babies & Children's Hospital Opens Most Technologically Advanced NICU in World 2Health News:Rainbow Babies & Children's Hospital Opens Most Technologically Advanced NICU in World 3Health News:Rainbow Babies & Children's Hospital Opens Most Technologically Advanced NICU in World 4Health News:'Above & Beyond Citizen Honors' Announces and Honors 2009 Recipients 2Health News:'Above & Beyond Citizen Honors' Announces and Honors 2009 Recipients 3Health News:'Above & Beyond Citizen Honors' Announces and Honors 2009 Recipients 4
... ,The Cardiocap/5 is a compact, ... the operating room, ambulatory surgery unit, ... offers full vital signs monitoring capabilities ... circulation to advanced airway gas analysis ...
... Releasing the power of clinical information. ... newest generation of clinical connectivity solutions that ... provide effective, high-quality patient care. You will ... be able to share it with your ...
... of clinical information. , ,S/5 Clinical ... connectivity solutions that help you and your ... care. You will have access to essential ... it with your care team and specialists, ...
... Compact and comprehensive solution for ... Arrhythmia Workstation (ARRWS) provides one compact, ... telemetry monitored patients. It connects to ... analysis for up to 16 beds., ...
Medicine Products: